吉非替尼治疗非小细胞肺癌51例疗效观察  

Clinical effect of Gefitinib(Iressa)in 51 cases of none-small cell lung cancer(NSCLC)

作　　者：谢晓冬[1] 郑振东[1] 屈淑贤[1] 刘大为[1] 张冠中[1] 刘永叶[1] 朴瑛[1] 刘艳梅[1] 单学健[1] 邢春景[1] 

机构地区：[1]沈阳军区总医院肿瘤科,辽宁沈阳110016

出　　处：《中国实用内科杂志》2007年第16期1287-1289,共3页Chinese Journal of Practical Internal Medicine

摘　　要：目的探讨吉非替尼（Gefitinib,Iressa）治疗非小细胞肺癌（non-small cell lung cancer,NSCLC）的疗效及毒副反应。方法回顾性分析2004年3月至2006年3月沈阳军区总医院肿瘤科51例采用单药口服吉非替尼250mg每日1次治疗并获得随访的NSCLC复治患者的临床资料,评价其临床疗效、生存质量、中位生存期、疾病进展时间及毒副反应。结果病灶总缓解率为29.4%,总控制率为66.7%,临床症状改善率为62.7%,服药4周内KPS评分提高与治疗前相比差异有显著性意义。患者中位生存期为8.2个月,疾病进展时间为6.1个月,未出现Ⅲ～Ⅳ级毒性反应。结论吉非替尼可以显著改善NSCLC患者的临床症状及生存质量,且耐受性良好,是一种适合国人的分子靶向治疗药物。Objective To ascertain clinical experience and toxic reactions of treating NSCLC by Gefitinib （Iressa）. Methods Clinical data of 51 NSCLC cases were collected and analyzed who were treated with Iressa from Mar. 2004 to Mar. 2006. Evaluations were made about curative effects, quality of life, mean survival time, time to progression and toxic reactions. Results Fifty-one patients were all followed up. Total mitigative rate of the focus was 29. 4% ,total control rate was 66.7% ,and alleviative rate of clinical symptoms was 62.7%. The difference of KPS grades in 4 weeks was significant. Mean survival time of all the patients was 8.2 months. Time to progression was 6. 1 months. Ⅲ～Ⅳ grades of toxic reaction were not found. Conclusion Gefitinib may obviously improve the clinical symptom and QOL of the NSCLC patients, and it has good tolerance to treat NSCLC. It is a kind of molecule-target medicine suited with Chinese.

关 键 词：吉非替尼 非小细胞肺癌 

分 类 号：R5[医药卫生—内科学]